PMID- 36266641
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221024
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Oct 20
TI  - Performance of BioFire Blood Culture Identification 2 Panel (BCID2) for the 
      detection of bloodstream pathogens and their associated resistance markers: a 
      systematic review and meta-analysis of diagnostic test accuracy studies.
PG  - 794
LID - 10.1186/s12879-022-07772-x [doi]
LID - 794
AB  - BACKGROUND: Early identification of bloodstream pathogens and their associated 
      antimicrobial resistance may shorten time to optimal therapy in patients with 
      sepsis. The BioFire Blood Culture Identification 2 Panel (BCID2) is a novel 
      multiplex PCR detecting 43 targets directly from positive blood cultures, 
      reducing turnaround times. METHODS: We have performed a systematic review and 
      meta-analysis of diagnostic test accuracy studies to assess the BCID2 performance 
      for pathogen identification and resistance markers detection compared to gold 
      standard culture-based methods (including phenotypic and/or genotypic 
      characterization). RESULTS: Nine studies were identified reporting data to build 
      2 x 2 tables for each BCID2 target, including 2005 blood cultures. The pooled 
      specificity of the assay was excellent (> 97%) across most subgroups of targets 
      investigated, with a slightly broader confidence interval for S. epidermidis 
      (98.1%, 95% CI 93.1 to 99.5). Pooled sensitivity was also high for the major 
      determinants of bloodstream infection, including Enterobacterales (98.2%, 95% CI 
      96.3 to 99.1), S. aureus (96.0%, 95% CI 90.4 to 98.4), Streptococcus spp. (96.7%, 
      95% CI 92.8 to 98.5), P. aeruginosa (92.7%, 95% CI 83.1 to 97.0), E. faecalis 
      (92.3%, 95% CI 83.5 to 96.6), as well as bla(CTX-M) (94.9, 95% CI 85.7 to 98.3), 
      carbapenemases (94.9%, 95% CI 83.4 to 98.6) and mecA/C & MREJ (93.9%, 95% CI 83.0 
      to 98.0). Sensitivity for less common targets was slightly lower, possibly due to 
      their under-representation in the included studies. CONCLUSIONS: BCID2 showed 
      good performance for detecting major determinants of bloodstream infection and 
      could support early antimicrobial treatment, especially for ESBL or 
      carbapenemase-producing Gram-negative bacilli and methicillin-resistant S. 
      aureus.
CI  - (c) 2022. The Author(s).
FAU - Peri, Anna Maria
AU  - Peri AM
AD  - University of Queensland Centre for Clinical Research, Herston, QLD, 4029, 
      Australia. a.peri@uq.edu.au.
FAU - Ling, Weiping
AU  - Ling W
AD  - University of Queensland Centre for Clinical Research, Herston, QLD, 4029, 
      Australia.
FAU - Furuya-Kanamori, Luis
AU  - Furuya-Kanamori L
AD  - University of Queensland Centre for Clinical Research, Herston, QLD, 4029, 
      Australia.
FAU - Harris, Patrick N A
AU  - Harris PNA
AD  - University of Queensland Centre for Clinical Research, Herston, QLD, 4029, 
      Australia.
AD  - Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, 
      Herston, QLD, 4029, Australia.
FAU - Paterson, David L
AU  - Paterson DL
AD  - University of Queensland Centre for Clinical Research, Herston, QLD, 4029, 
      Australia.
AD  - Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, QLD, 
      4029, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221020
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Humans
MH  - Blood Culture
MH  - *Bacteremia/diagnosis
MH  - *Methicillin-Resistant Staphylococcus aureus
MH  - Staphylococcus aureus
MH  - Diagnostic Tests, Routine
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
PMC - PMC9585790
OTO - NOTNLM
OT  - BCID2
OT  - Blood culture
OT  - Bloodstream infection
OT  - Meta-analysis
OT  - Molecular diagnostic techniques
OT  - Sepsis
COIS- DLP has received honoraria for speaking for bioMerieux. The other authors declare 
      no conflict of interest.
EDAT- 2022/10/22 06:00
MHDA- 2022/10/25 06:00
PMCR- 2022/10/20
CRDT- 2022/10/21 00:01
PHST- 2022/05/23 00:00 [received]
PHST- 2022/10/09 00:00 [accepted]
PHST- 2022/10/21 00:01 [entrez]
PHST- 2022/10/22 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
PHST- 2022/10/20 00:00 [pmc-release]
AID - 10.1186/s12879-022-07772-x [pii]
AID - 7772 [pii]
AID - 10.1186/s12879-022-07772-x [doi]
PST - epublish
SO  - BMC Infect Dis. 2022 Oct 20;22(1):794. doi: 10.1186/s12879-022-07772-x.